A chemokine, monocyte chemoattractant protein 1 (MCP-1), attracts macrophages. The production of MCP-1 is enhanced in keratinocytes of psoriatic lesions, which may contribute to macrophage infiltration into the lesions. It is known that estrogen regulates the course of psoriasis. We examined in vitro effects of 17b-estradiol (E2) on MCP-1 production by human keratinocytes. E2 inhibited constitutive and 12-O-tetradecanoylphorbol-13-acetate-induced MCP-1 secretion, mRNA expression, and promoter activity in keratinocytes, and these effects of E2 were counteracted by estrogen receptor antagonist ICI 182 780. GC-rich Spl element and activator protein 1 (AP-1) element on MCP-1 promoter were required for constitutive and 12-Otetradecanoylphorbol-13-acetate-induced transcription, respectively, and involved in transrepression by E2. E2 inhibited constitutive Spl and 12-O-tetradecanoylphorbol-13-acetate-induced AP-1 transcriptional activities whereas it did not inhibit DNA binding of Sp1 or AP-1 c-Fos/c-Jun. E2 inhibited Sp1 and AP-1 transcriptional activities and MCP-1 promoter activity in estrogen receptor P (ERb) transfected SKBR3 cells. Deletion of the A/B region or mutation of activation function 2 in ERb abrogated E2-dependent transcriptional inhibition by ERb whereas mutation of DNA-binding domain retained the inhibitory effects. Transfection of ERb enhanced the inhibitory effects of E2 on Sp1 and AP-1 transcriptional activities and MCP-1 promoter activities in nontransfected keratinocytes. Coimmunoprecipitation studies showed an E2-dependent association of ERb with Sp1 or AP-1 in ERb-transfected keratinocytes. These results suggest that E2-bound ERb may inhibit MCP-1 gene expression by inhibiting Sp1 and AP-1 transcriptional activities in keratinocytes. A/B region and intact activation function 2 of ERb may be responsible for the effects of E2. Key words: AP-1/estrogen receptor/Sp1. J Invest Dermatol 120: [1058][1059][1060][1061][1062][1063][1064][1065][1066] 2003 Psoriasis is characterized by epidermal hyperplasia associated with vascular proliferation and inflammatory infiltrates (Bos and de Rie, 1999) . Numerous macrophages arc accumulated in papillary dermis of psoriatic skin lesions, which may be the source of proinflammatory cytokines such as tumor necrosis factor a (TNF-a) or interleukin-1 (IL-1) (Giustizieri et al., 2001) . Monocyte chemoattractant protein 1 (MCP-1) is thought to be a primary chemokine attracting macrophages into psoriatic lesions (Gillitzer et al., 1993) , and may function as a mediator for acute and chronic inflammation (Conti and DiGioacchino, 2001) . It is reported that MCP-1 production by keratinocytes is increased in psoriatic skin lesions (Gillitzer et al., 1993) . Thus the blockage of MCP-1 production in keratinocytes is a key therapeutic target for psoriasis.
Psoriasis is characterized by epidermal hyperplasia associated with vascular proliferation and inflammatory infiltrates (Bos and de Rie, 1999) . Numerous macrophages arc accumulated in papillary dermis of psoriatic skin lesions, which may be the source of proinflammatory cytokines such as tumor necrosis factor a (TNF-a) or interleukin-1 (IL-1) (Giustizieri et al., 2001) . Monocyte chemoattractant protein 1 (MCP-1) is thought to be a primary chemokine attracting macrophages into psoriatic lesions (Gillitzer et al., 1993) , and may function as a mediator for acute and chronic inflammation (Conti and DiGioacchino, 2001) . It is reported that MCP-1 production by keratinocytes is increased in psoriatic skin lesions (Gillitzer et al., 1993) . Thus the blockage of MCP-1 production in keratinocytes is a key therapeutic target for psoriasis.
It is reported that the natural course of psoriasis is modulated by pregnancy (Farber and Nall, 1974; Dunna and Finlay, 1989; Boyd et al., 1996) , menstruation (Stevens et al., 1993; Boyd and King, 1999) , or menopause (Mowad et al., 1998) . These indicate the modulatory role of sex hormones, especially estrogen, in the pathogenesis of psoriasis. We recently found that 17b-cstradiol (E2) acted on human keratinocytes and inhibited their interferon-ginduced production of IP-10, which chemoattracts T helper 1 cells (Kanda and Watanabe, 2003a) . It is thus anticipated that E2 may also inhibit MCP-1 production in human keratinocytes. The effects of E2 on MCP-1 production have been studied in several other cell types; however, the results arc conflicting: E2 inhibited lipopolysaccharide-induced JE/MCP-1 production in murine macrophages in vitro (Frazier-Jessen and Kovacs, 1995) whereas it enhanced IL-1-induced MCP-1 production in human endometrial cells in vitro (Akoum et al., 2000) and MCP-1 production in murine splenocytes in vivo (Matejuk et al., 2002) . Thus the effects of E2 on MCP-1 production appear to differ depending on cell type or experimental conditions. Precise mechanisms for the differential effects have not been elucidated, however.
E2 exerts its effects via intracellular estrogen receptor (ER); E2-bound ER upregulates or downregulates the transcription of various genes by binding to estrogen response element of the target genes (Beato, 1989) or by interacting with other transcription factors such as activator protein 1 (AP-1) (Paech et al., 1997) or Sp1 (Safe, 2001) . ER exists as two subtypes, ERa and ERb, encoded by separate genes (Mosselman et al., 1996; Mendelsohn and Karas, 1999) . ERa and ERb show overlapping and differential effects on gene expression. We previously found that human keratinocytes express ERb but not ERa (Kanda and Watanabe, 2003a, b) , indicating that E2 exerts its effects via ERb in keratinocytes.
In this study, we investigated in vitro effects of E2 on MCP-1 production in human keratinocytes. Full-length cDNA encoding human MCP-1 has been cloned from human glioma cell lines (Yoshimura et al., 1989) . MCP-1 production can be induced by proinflammatory cytokines such as TNF-a or phorbol esters such as 12-O-tetradecanoylphorbol-13-acetate (TPA) (Ueda et al., 1994) . TPA in vivo induces psoriasiform skin inflammation and epidermal hyperplasia in mice (Reynolds et al., 1997) , and in vitro induces keratinocytes to express IL-8 (Barker et al., 1991a) or intercellular adhesion molecule 1 (Griffiths et al., 1990) , both of which are highly related to the pathogenesis of psoriasis. In addition keratinocytes from patients with psoriasis show extremely enhanced responses to TPA in MCP-1 and IL-8 production compared to those from healthy controls (Giustizieri et al., 2001) . Thus TPA appears to be properly used as a stimulus in the model system for MCP-1 production in psoriatic skin lesions. TPA mainly promotes the transcriptional activity of AP-1, and the 5 0 -flanking region in MCP-1 gene contains AP-1 binding sites (Shyy et al., 1990 ). Although we found that E2 inhibited TNF-a or IL-1 (b-induced RANTES production in keratinocytes (Kanda and Watanabc, 2003b ), we have not examined the effects of E2 on TPAinduced chemokine expression in keratinocytes. Thus in this study we aimed to investigate whether E2 may alter TPA-induced MCP-1 production in keratinocytes. We found that E2 inhibited both constitutive and TPA-induced MCP-1 production in keratinocytes at transcriptional level. We further examined precise mechanisms for the effects, focusing on E2-induced modulation of the activities of transcription factors Sp1 and AP-1.
MATERIALS AND METHODS

Reagents
E2 and TPA were purchased from Sigma (St. Louis, MO). ICI 182 780 was from Wako Pure Chemical Industries (Osaka, Japan). Antibodies used in the electrophorctic mobility shift assay (EMSA), immunoprecipitation, or western blot were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Culture of normal human epidermal keratinocytes
Human neonatal foreskin keratinocytes were cultured in serum-free kcratinocytc growth medium (KGM) (Clonetics, Walkersville, MD) with 0.1 mM of calcium ion, consisting of basal medium MCDB153 supplemented with 0.5 pg per ml hydrocortisone, 5 ng per ml epidermal growth factor, 5 pg per ml insulin, and 0.5% bovine pituitary extract. The cells in third passage were used for the experiments.
Reverse transcription polymerase chain reaction (RT-PCR)
Keratinocytes were incubated as above for 6 h, and RNA was extracted using mRNA purification kit (Pharmacia, Uppsala, Sweden) according to the manufacturer's instruction. cDNA was made from RNA samples as described previously (Tjandrawinata et al., 1997) . Primers for amplification and the sizes of respective PCR products were as follows: MCP-1, 5 0 -CCCAGGGGTAGAACTGTGGTTCAA-3 0 (sense) and 5 0 -CTGGCTCAGCCAGATGCAATCAAT-3 0 (antisense) for 480 bp (Jedrzkicwicz et al., 1999) ; glyccraldchydc-3-phosphate dehydrogenase (GAPDH), 5 0 -CCACCCATGGCAAATTCCATGGCA-3 0 (sense) and 5 0 -TCTACACGGCAGGT-CAGGTCCACC-3 0 (antisense) for 600 bp (Hu et al., 1999) . PCR was performed by one denaturing cycle of 95 1C for 3 minutes, 30 cycles of denaturation at 95 1C for 30 seconds, annealing at 58 1C for 30 seconds, extension at 72 1C for 30 seconds, and a final extension at 72 1C for 3 minutes. The PCR products were analyzed by electrophoresis on 2.5% agarose gels and stained with ethidium bromide, viewed by ultraviolet light, and photographed. Densitometric analysis was performed by scanning the bands into Photoshop and performing densitometry with NIH Image Software.
Plasmids
Firefly luciferase reporter plasmids driven by human MCP-1 promoters (À2910/ À1 bp and À213/À1 bp relative to the translational start site), denoted as pMCP-1 (2910) luc and pMCP-1 (213) luc, were constructed by PCR and insertion into pGL3 basic vectors (Promega, Madison, WI) as described previously (Li and Kolattukudy, 1994; Valente et al., 1998; Zhou et al., 1998) . p4 Â AP-1-TATA-luc and p4 Â Spl-TATA-luc were constructed by inserting four copies of distal AP-1 binding element (5 0 -TTATCACTCATGG-3 0 , with consensus sequences underlined) or GC-rich Sp1 binding sequences (5 0 -ACTCCGCCCTCT-3 0 ) from human MCP-1 promoter in front of the TATA box upstream of firefly luciferase reporter as described by Philips et al. (1993) . pCMV-ERb expressing full-length human ERb (477 amino acids) was constructed as described previously (Bhat et al., 1998) . Site-specific mutations of MCP-1 promoter or ERb expression vector were created by multiple rounds of PCR using appropriate primers with altered bases as described before (Kunkel et al., 1987; Zhou et al., 1998; Mak et al., 1999; Jakacka et al., 2001) . N-terminal deletion mutants, ERb A/B (À), which delete amino acids 1-96 of ERb (Fig 5) , were constructed by PCR using primers containing appropriate truncation as described by Weatherman and Scanlan (2001) .
Transfections
Transient transfections were performed with Effcctene (Qiagcn, Tokyo, Japan) as described previously (Zellmer et al., 2001) . Keratinocytes were plated in 10 cm dishes and grown to about 60% confluence. Twenty-four hours before the transfection, the medium was changed to phenol-red-free KBM. Keratinocytes in KBM were incubated for 6 h with 5 mg of pMCP-1 (2910 or 213) luc or p4 Â AP-1-TATA-luc or p4 Â Spl -TATA-luc and 1 mg of Rous sarcoma virus b-galactosidase vector (pRSV-Pgal), prcmixed with enhancer, transfection buffer, and Effcctene. The transfected cells were washed and incubated in KBM for 18 h, and then treated with E2 for 10 minutes prior to the addition of TPA. After 24 h, cell extracts were prepared and luciferase activities were quantified using the luciferase assay system (Promega). The same cell extracts were assayed for b-galactosidase activity using chemiluminescent Galacto-Light kit (Tropix, Bedford, MA). All readings were taken using a Lumat 9501 luminometer (Berthold, Wildbach, Germany). The results obtained in each transfection were normalized for (b-galactosidasc activity and expressed as relative luciferase activity. Human breast carcinoma SKBR3 cells (ERa-and ERb-negativc) (Dainippon Pharmaceuticals, Osaka, Japan) were maintained with a 1:1 mixture of Dulbccco's modified Eagle's medium (DMEM):-Ham's F-12 medium (Invitrogcn, Grand Island, NY) supplemented with 10% fetal bovine serum. SKBR3 cells were transfected with 5 mg of pMCP-1 (213) luc, p4 Â AP-1-TATA-luc, or p4 Â Spl-TATA-luc, and 1 mg of pRSV-Pgal, with 1 mg wildtype or mutated pCMV-ERb or empty pcDNA3 vector using Effcctene in scrum, and phenol-red-free DMEM:F-12 (1:1). ERb expression vector was similarly transfected into keratinocytes except for using KBM.
EMSA
The probes used were annealed double-stranded DNA containing distal AP-1 sequences (5 0 -ATTTAACAGCCCACTTATCAC-TCATGGAA-3 0 ) or Sp1 binding sequences (5 0 -CGTGCTGCTTGACT-CCGCCCTCTCTCCC-3 0 ) from human MCP-1 promoter, or consensus estrogen response element (5 0 -CAAAGTCAGGTCACAGT-GACCTGAT-GAAT-3 0 ) from vitellogenin A2 gene. The probes were labeled by incorporation of [ 32 P]dCTP with Klenow DNA polymerase. For gel shift assays, 2-5 pg of nuclear protein extracts were incubated at room temperature for 5 minutes with a mixture containing 6 mM HEPES (pH 7.9), 0.4 mM ethylenediamine tetraacetic acid (EDTA), 125 mM KC1, 10% glycerol, 0.05 mg per ml poly dI-dC, 1 mM dithiothreitol, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na 3 V0 4 , 10 mM NaF, 50 mg per ml aprotinin, and 50 mg per ml leupeptin. Approximately 1 ng labeled probe was added and the reactions were incubated at room temperature for another 20 minutes. In antibody supershift experiments, the nuclear extracts were preincubated with antibodies against various transcription factors on ice for 30 minutes before the addition of probe. Reactions were then fractionated on a nondenaturing 5% polyacrylamide gel. The gels were dried and visualized with phosphorimager (Molecular Dynamics, Sunnyvale, CA).
Western blotting
ER-transfected SKBR3 cells were lyzed in lysis buffer [20 mM Tns (pH 8.0), 0.1 M NaCl, 0.5% Nonidct p-40, 1 mM EDTA, 1 mM phcnylmcthylsulfonyl fluoride (PMSF), 1 mg per ml leupeptin, 1 mg per ml pepstatin, 1 mM dithiothreitol]. The lysatcs were centrifuged (8000g 5 minutes) and the protein concentration of the supcrnatants was determined by Bio-Rad protein assay reagents (Bio-Rad, Hercules, CA). Twenty micrograms of total cellular protein was clectrophoresed by sodium dodccyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane. The membrane was blocked and incubated with 1 pg per ml of goat IgG anti-ERb antibody recognizing the carboxy terminus, and then incubated with horseradish-pcroxidase-conjugated secondary antibody and developed by enhanced chemi-luminescence (Amersham, Arlington Heights, IL).
Immunoprecipitation and immunoblotting
Immunoprecipation and immunoblotting were performed as described previously (Teyssier et al., 2001) . ERb-transfccted keratinocytes were preincubated with 10 À8 M E2 for 10 minutes, and then incubated with medium alone or with TPA 10 nM for 30 minutes in the presence or absence of E2. Whole cell extracts were prepared in lysis buffer [50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM Na 3 V0 4 , 20 mM b-glyccrol phosphate, 1 mM PMSF, 1 mg per ml leupeptin, 2 mg per ml aprotinin, 1 mg per ml pepstatin, 1% Nonidet p-40, 0.25% deoxycholatc, and 0.1% SDS]. Extracts were immunoprecipitated with 10 mg per ml of goat polyclonal anti-ERb antibody (L-20) (Santa Cruz Biotechnology). The immune complexes were captured on protein G-Sepharose beads (Pharmacia, Piscataway, NJ) for 1 hour at 4 1C. Precipitated proteins were washed with lysis buffer, separated by SDS-PAGE, and transferred to a nitrocellulose membrane. The membrane was blocked and incubated with 1 mg per ml of rabbit polyclonal anti-c-Jun (H-79), c-Fos (H-125), or Sp1 (PEP2) antibodies (Santa Cruz Biotechnology), and then incubated with horseradish-pcroxidase-conjugated mouse antirabbit IgG (Santa Cruz Biotechnology) and developed. Following the analysis of c-Jun, c-Fos, or Sp1, the blots were stripped and reprobed with anti-ERfi antibody as described above.
RESULTS
E2 inhibited basal and TPA-induced MCP-1 secretion
Keratinocytes constitutivcly secreted MCP-1 (mean±SEM 105 ± 13 pg per ml, n ¼ 5), and TPA 10 nM increased the secretion up to 662 ± 63 pg per ml (n ¼ 5). E2 concentration-dependently reduced both constitutive and TPA-induced MCP-1 secretion (Fig 1) ; a significant effect of E2 occurred at 10 À10 M, increased concentrationdependently, and reached a maximum at 10 À8 M, which inhibited constitutive or TPA-induced MCP-1 secretion by 67 or 60%, respectively. ER antagonist IC1 182,780 alone did not alter constitutive or TPA-induced MCP-1 secretion in the absence of E2; however, it counteracted the E2-mediatcd inhibition of constitutive or TPA-induced MCP-1 secretion (Fig 1) , indicating that the effects of E2 may be mediated via ER. We then examined whether E2 may inhibit constitutive or TPA-induced MCP-1 mRNA expression in keratinocytes.
E2 inhibited constitutive and TPA-induced MCP-1 mRNA expression E2 suppressed constitutive or TPA-induced MCP-1 mRNA expression by 70 or 69% of controls, respectively (Fig 2) . These effects of E2 were counteracted by ICI 182,780. Thus E2 inhibited constitutive or TPA-induced MCP-1 production at pretranslational level. We then examined whether E2 may suppress basal or TPA-induced MCP-1 promoter activity.
E2 inhibits basal and TPA-induced MCP-1 promoter activity
We transiently transfected human MCP-1 promotcr-luciferase reporter constructs into keratinocytes, and the promoter activity was assessed by the relative lucifcrase activity of the cell lysates. Basal promoter activity was confirmed using pMCP-1 (2910) luc, a construct containing 2910 bp upstream of the translational start site, and TPA increased the activity 5.3-fold (Fig 3b, uppermost four columns). E2 reduced basal or TPA-induced activity of wild-type MCP-1 promoter by 68 or 60% of controls, respectively (Fig 3b, uppermost four columns), and these effects of E2 were counteracted by ICI 182 780 (data not shown). A construct containing 213 bp upstream of the translational start site, pMCP-1 (213) luc, was fully capable of showing basal and TPA-induced MCP-1 promoter activity and E2-mcdiatcd inhibition (Fig 3b, second four columns) , as well as pMCP-1 (2910) luc. Thus the downstream 213 bp clement appeared to fully direct basal and TPA-induced promoter activity and E2-mediated inhibition in keratinocytes. Although the MCP-1 5 0 -flanking sequence À2910/À2111 bp (distal enhancer region) contains two nuclear factor kB (NF-kB) binding sites and one AP-1 binding site (Ueda et al., 1994) , mutation of these elements did not abrogate the basal and TPA-induced MCP-1 promoter activities and E2-mcdiated inhibition (data not shown), indicating that these elements may be dispensable at least for unstimulated or TPAstimulated keratinocytes. Thus further experiments were performed using pMCP-1 (213) luc.
The 213 bp MCP-1 promoter contains a number of putative nwcting elements that may contribute to the promoter activity (Fig  3a) . We thus examined which of these elements may be responsible for the inhibition by E2 of the basal or TPA-induced MCP-1 transcription, by using mutated promoters. The mutation of GC-rich Sp1 binding clement mostly abrogated the basal promoter activity and the suppression by E2 of the basal activity; however, it retained the fold induction by TPA and the suppression by E2 of the response to TPA (Fig 3b, lowermost four columns) . This indicates that the Sp1 element may be mainly responsible for the basal promoter activity and may be involved in E2-induced suppression of the basal activity. On the other hand, mutation of the distal AP-1 element abrogated TPA-induced promoter activation but retained the basal promoter activity (Fig 3b, third four columns) , suggesting that the distal AP-1 element may be mainly responsible for the induction by TPA. The activity of distal AP-1-mutated promoter was suppressed by E2 in the presence or absence of TPA (Fig 3b, third four columns) , possibly reflecting its suppression of basal activity and not of the response to TPA. Mutation of NF-kB or the proximal AP-1 clement did not alter basal promoter activity or the induction by TPA, and suppressive effects of E2 on basal and TPA-induced promoter activities (Fig 3b, fourth and fifth four columns), indicating that these elements may be dispensable for the basal and TPA-induced promoter activities and may not be involved in the suppressive effects of E2. These results suggest that the Sp1 element may be responsible for the basal MCP-1 promoter activity and E2-induced inhibition of the constitutive transcription whereas the distal AP-1 element may be involved in TPA-induced promoter activity and E2-mediatcd inhibition of the response to TPA. We then analyzed if E2 may suppress transcription through the distal AP-1 or Sp1 element in keratinocytes. in front of the luciferase reporter, and were incubated with E2 in the presence or absence of TPA. The transcriptional activity through the Sp1 clement was constitutively high in keratinocytes, and was not enhanced by TPA (Fig 4, uppermost four columns) . E2 suppressed the transcriptional activity through Sp1 in the presence or absence of TPA. The transcriptional activity through distal AP-1 was minimal in unstimulated keratinocytes, and was enhanced by TPA (Fig 4,  second four columns) . E2 suppressed the TPA-induced transcriptional activity through AP-1. ICI 182,780 counteracted the E2-mcdiatcd inhibition of basal transcriptional activity through Sp1 or TPA-induced transcriptional activity through AP-1 (data not shown).
E2 inhibited Sp1 or AP-1 transcriptional activities and MCP-1 promoter activity via ERb
It appeared that ERb mediated E2-induced inhibition of Sp1 or AP-1 transcriptional activities and MCP-1 promoter activity in keratinocytes as keratinocytes express ERb but not ERa (Kanda and Watanabc, 2003a, b) . To further test this hypothesis, we examined if transfection of ERb into ER-ncgative cells may result in E2-mediated inhibition of these activities. E2 did not inhibit Sp1 or AP-1 transcriptional activities or MCP-1 promoter activity in cither the presence or the absence of TPA in ER-ncgative SKBR3 cells transfectcd with empty pcDNA3 vector (Fig 6a, b, c, d , upper panel, lanes 1, 2). ERb transfection per se did not alter these activities in the absence of E2 (Fig 6a, b, c, d , upper panel, lane 3); however, E2 suppressed constitutive Sp1 activity (Fig 6a or MCP-1 promoter activity (Fig 6b) and TPA-induced AP-1 activity (Fig 6c) or MCP-1 promoter activity (Fig 6d, uppa panel, lanes 4 ) in ERb-transfected SKBR3 cells. These findings suggest that suppressive effects of E2 in SKBR3 cells may be mediated via transfectcd ERb. In keratinocytes transfectcd with empty pcDNA3, E2 suppressed constitutive Sp1 activity (Fig 6a) or MCP-1 promoter activity (Fig 6b) and TPAinduced AP-1 activity (Fig 6c) or MCP-1 promoter activity (Fig 6d, Iowa panel, lanes 2) by 60%-70% of controls, and the inhibitory effects of E2 were further enhanced by the transfection of ERb, about 90% inhibition versus controls (Fig 6a, b, c, d , lower panel, lane 3).
These findings indicate that E2 may suppress MCP-1 expression via both endogenous and transfectcd ERb in keratinocytes. ER is composed of A to F regions: the N-tcrminal A/B region containing a ligand-independent transcriptional activation function, the DNA-binding C region, the hinge region D, an E region containing a ligand-binding domain and ligand-dependent transcriptional activation function (AF-2), and the C-terminal F region (Fig 5a) . We then analyzed which rcgion(s) of ERb may be involved in the E2-induced suppression of Sp1, AP-1 activities, and MCP-1 promoter activity by transfecting mutant ERb into SKBR3 cells. Transfection of the A/B-region-delcted ERb into SKBR3 cells did not reduce constitutive Sp1 activity or MCP-1 promoter activity and TPA-induced AP-1 activity or MCP-1 promoter activity in the presence of E2 (Fig 6a, b, c, d , upper panel, lanes 5). This indicates that the A/B region of ERb may be primarily responsible for the inhibitory effects of E2. To determine the requirement of ERb DNAbinding domain (DBD) for E2-mcdiated effects, mutations were introduced into DBD by substituting alanine residues: ERb E114A/ G115A, which cannot bind to oligonucleotide probe containing consensus estrogen response clement in EMSA (data not shown; Jakacka et al., 2001) . In ERb E114A/G115A-transfccted cells, E2 showed inhibitory effects (Fig 6a, b, c, d , upper panel, lanes 6), in a manner similar to those in wild-type ERb-transfected cells (Fig 6a, b , c, d, upper panel, lanes 4) , indicating that ERb DBD may be dispensable for E2-induced suppression of Sp1 and AP-1 activities, or MCP-1 promoter activities. AF-2 of ERb plays in important role in the interaction with transcriptional coactivators (Mak et al., 1999) , and two different point mutations (ERP L437A/E440A) were introduced into ERb helix 12 of the AF-2 surface, which disrupts interactions with pl60 family coactivators and E2-induced transcription from estrogen response element (Mak et al., 1999) . In ERb L437A/E440A-transfected cells, E2 did not suppress Sp1 or AP-1 activity or MCP-1 promoter activities (Fig 6a, b, c, d , upper panel, lanes 7), indicating that an intact AF-2 surface may be required for the transcriptional repression by E2.
E2 did not alter DNA binding of Sp1 or AP-1
We then examined if E2 may suppress DNA binding of transcription factors at the Sp1 or AP-1 element. As inhibitory effects of E2 on Sp1 and AP-1 activities were most remarkably seen in ERb-transfected kcratinocytcs (Fig 6) , nuclear extracts from these cells were used for EMSA. Nuclear extracts from ERb-transfectcd keratinocytes without TPA stimulation formed a DNA-protcin complex with the Sp1-elemcnt-containing probe (Fig 7a, lane 2) , and the amount of the complex was not reduced by E2 (Fig 7a, lane 3) . Anti-Spl antibody (Fig 7a, lane 4) but not anti-Sp2, Sp3, Sp4, or AP-2 antibodies (data not shown) supershifted the complex with the Sp1 probe, indicating the presence of Sp1 in the complex. The amount of DNA-protcin complex with Sp1 probe was not altered by TPA in the presence or absence of E2 (Fig 7a, lanes 7, 8) . The nuclear extracts from ERbtransfected keratinocytes without TPA stimulation formed a small amount of DNA-protein complex with distal AP-1-containing probe (Fig 7b, lane 2) , and the amount was increased by TPA (Fig 7b, lane  4) . The addition of E2 did not reduce the amount of basal or TPAinduced complexes with AP-1 probe (Fig 7b, lanes 3, 5) . Anti-c-Jun and c-Fos antibodies (Fig 7b, lanes 6, 7) but not anti-JunB, JunD, FosB, Fra-1, or Fra-2 antibodies (data not shown) supershifted the DNA-protcin complex with AP-1 probe, indicating that the complex may be composed of c-Fos/c-Jun heterodimers. These results indicate that E2 may inhibit the transactivation ability of Sp1 or AP-1 without inhibiting their DNA binding. We then examined the presence of ERb in the Sp1 or AP-1 complex with DNA by using anti-ERP antibody, which supershifted ERb bound to estrogen response element (Fig 7c) . Faint but significant supershifted bands by anti-ERb (Fig 7a, lane 5; Fig 7b, lane 8) were obtained with the Sp1 or AP-1 complex from nuclear extracts treated with E2, but the supershifts were not obtained from nuclear extracts without E2 treatment (Fig 7a, lane 6; Fig 7b, lane 9) . This indicates the presence of ERb in the protcin-DNA complex and E2-dcpendcnt interaction of ERb with Sp1 or AP-1. The supershiftcd bands by anti-ERP antibody were not obtained in nuclear extracts from keratinocytes KANDA AND WATANABE without ERb transfection (data not shown), possibly because the amount of endogenous ERb associated with Sp1 or AP-1 may be lower and thus undetectable by the antibody, and/or the epitope for the antibody on ERb may be masked by the interaction with Sp1 or AP-1.
The E2-dependent association of ERb with Sp1 or AP-1 was further investigated by coimmunoprecipitation studies. Whole cell extracts from ERb-transfected keratinocytes were immunoprecipitated with anti-ERb antibody, and then immunoblotted by anti-Sp1, c-Jun, or c-Fos antibodies. Sp1 protein was detected in anti-ERb immunoprecipitatcs from ERb-transfected keratinocytes cultured in the presence but not in the absence of E2 (Fig 8a) . Sp1 was also detected in anti-ERP immunoprccipitates from ERfi-transfected keratinocytes treated with TPA plus E2 but not with TPA alone (data not shown). c-Jun and c-Fos proteins were detected in anti-ERb immunoprecipitatcs from ERb-transfectcd keratinocytes treated with TPA in the presence but not in the absence of E2 (Fig 8b) . c-Jun and c-Fos were not detected in anti-ERP immunoprecipitatcs from ERbtransfectcd keratinocytes treated with E2 alone without TPA (data not shown). These results demonstrate that ERb could interact with Sp1 or AP-1 proteins in an E2-depcndcnt manner.
DISCUSSION
This study demonstrated that E2 inhibited constitutive and TPAinduced MCP-1 transcription in human neonatal foreskin keratinocytes by inhibiting transcriptional activity of Sp1 and AP-1, respectively. These effects of E2 appeared to be mediated via ERb. We also preliminarily found that keratinocytes from le-sional skin of psoriasis showed enhanced basal and TPA-induced MCP-1 secretion and mRNA expression compared to normal foreskin keratinocytes, and that the MCP-1 expression in psoriatic keratinocytes was suppressed by E2 as well as normal foreskin keratinocytes (data not shown). The element conferring response to TPA on MCP-1 promotet appeared to differ depending on cell type: the AP-1 binding site (À157/À151 bp relative to the translational start site) in keratinocytes and glioblastoma U138-MG (Li and Kolattukudy, 1994) , and the far upstream NF-kB clement (À2612/À2603 bp relative to the transcriptional start site, corresponding to À2672/ À2663 bp relative to the translational start site) in glioblastoma A172 and fibrosarcoma HT1080 (Ueda et al., 1994) . Such discrepancy may possibly be due to the cell type specificity in the relative amounts or activities of transcription factors or the activities of signaling molecules regulating transcription factor activities. At least in human keratinocytes, the far upstream NF-kB site may not be involved in TPA-induced MCP-1 transcription and E2-mcdiatcd inhibition of the response to TPA (Fig 3) . This element may act as the target for the inhibitory effects of E2 in the other cell types, however; it was required for IL-la-induced MCP-1 transcription in mammary carcinoma MCF-7 and the transcription was inhibited by E2 partially via inhibiting the DNA binding of NF-kB at this element (Inadera et al., 2000) . As IL-1a and IL-1b, which may potentiate NFkB activity, did not induce MCP-1 production in human kcratinocytes (our unpublished observation), we should further examine if other stimuli such as lipopo-lysaccharidc may induce MCP-1 transcription through this NF-kB clement (À2672/À2663 bp) in keratinocytes and if E2 may suppress the NF-kB-dependent MCP-1 transcription.
Previous studies reported that E2 inhibited Sp1 or AP-1-mediatcd gene expression via ERb Zou et al., 1999; Saville et al., 2000; Sawada et al., 2000; Maruyama et al., 2001; Safe, 2001) . In kcratinocytes, the A/B region and intact AF-2 structure of ERb were required for E2-mcdiatcd inhibition of Sp1 or AP-lmediated transcription (Fig 6) . On the other hand, mutation of DBD in ERb did not disrupt the inhibitory effects of E2 (Fig 6) , indicating that the effects of E2 may not be mediated by ER-DNA interaction but by the interaction of ER and Sp1 or AP-1 proteins. The results in coimmunoprecipitation assays (Fig 8) indicate that ERb may interact with Sp1 or AP-1 in the presence of E2. As an intact coactivator interaction surface of AF-2 was required for the transcriptional repression by E2 (Fig 6) , the AF-2 surface of E2-bound ERb may interact with the following transcriptional coactivators tethered to Sp1 or AP-l on DNA: p300/CREB-binding protein (Kamei et al., 1996; Naar et al., 1998) , SNURF (Saville et al., 2002) , pl60 family GRIP1, or novel coactivator CAPER (Teyssier et al., 2001; Jung et al., 2002) . E2-bound ERb may interact with AP-1 or Sp1/ coactivator complex bound onto DNA and act as a transcriptional coreprcssor; possibly the A/B region of ERb may inhibit the interaction of the above-mentioned complex with general transcriptional components like TATA-associatcd factors and/or inhibit the release of transcriptional corepressors. ER contains two dimerization domains, one in DBD, which is involved in ligand-independent dimerization, and the other in the ligand-binding domain mediating ligand-dependent dimerization (Chen et al., 1999) . The ERfi-mediatcd suppression of Sp1 or AP-1 activity was E2-dependent and DBD was dispensable for the suppression (Fig 6) . Thus E2-bound ERb may dimcrize through the dimerization domain in the ligand-binding domain and such dimers may interact with Sp1 or AP-1/coactivator complex. Alternatively, dimerization may not be required for the suppression of Sp1 or AP-1-mediated transcription by E2-bound Ellp as DBD was dispensable for the suppression and thus E2-bound ERb may not directly bind to DNA. Sawada et al (2002) also reported that ER dimerization inhibitor YP537 did not reverse the inhibitory effect of E2 on AP-1 transcriptional activity in dopaminergic neurons.
Our results suggest that E2 may inhibit MCP-1 production in the skin in the unstimulated state or under AP-1-driving stimuli such as oxidative stress, ultraviolet irradiation, bacterial superanti-gen, or hapten (Miyazaki et al., 2000) . The actions of E2 may differ on MCP-1 induction by proinflammatory cytokines such as IFN-a or TNF-a, however, in comparison to theTPA-induced system. As these cytokines, either alone or together, can induce MCP-1 production in kcratinocytes (Barker et al., 1991b; Li et al., 2000; Giustizieri et al., 2001) , further studies should examine if E2 may suppress IFNa and/or TNF-a-induced MCP-1 production in keratinocytes. In addition to MCP-1, E2 inhibited the production ot RANTES, another chemokine attracting macrophages, in human kcratinocytes (Kanda and Watanabc, 2003b) . Taken together, E2 may be therapeutically useful for the treatment of macro-phagc-involving inflammatory skin diseases like psoriasis. Estrogen may have another antipsoriatic effect; estrogen inhibits the induction of epidermal ornithine decarboxylase, required for DNA replication, indicating that estrogen may inhibit keratino-cyte hypcrprolifcration occurring in psoriasis (Arnold et al., 1993) . The effects of estrogen on skin in vivo have recently been studied; topical or systemic estrogen treatment is known to prevent skin aging whereas it may cause skin hyperpigmentation (Sator et al., 2001; Shah and Maibach, 2001 ). Therapeutic effects of estrogen on psoriasis, however, have hardly been studied in vivo. Only one study reported that combinational use of estrogen with cor-ticosteroid reduced the dose of the latter drug required for a psoriatic patient, indicating the synergistic effect of estrogen (Spangler et al., 1969) . Additional insights into the therapeutic effects of estrogen on psoriasis may be provided by prospective studies of postmenopausal patients with hormone replacement therapy or patients taking fertility drugs or oral contraceptives. 
